Skip to main content

Advertisement

SpringerLink
Log in

The epidemic of pre-injury oral antiplatelet and anticoagulant use

  • Review Article
  • Published:
European Journal of Trauma and Emergency Surgery Aims and scope Submit manuscript

Abstract

Background

As the population ages, an increasing number of trauma patients are taking antiplatelet and anticoagulant medications (ACAP) prior to their injuries. These medications increase their risk of hemorrhagic complications, particularly intracerebral hemorrhage. Clopidogrel and warfarin are common and their mechanisms well understood, but optimal reversal methods continue to evolve. The novel direct thrombin and factor Xa inhibitors are less well described and do not have existing antidotes.

Methods

This article reviews the relevant literature on traumatic outcomes with use of ACAP medications, as well as data on ideal reversal strategies. Suggested algorithms are introduced, and future research directions discussed.

Results

Although they are beneficial in preventing clot formation, once bleeding occurs ACAP medications contribute to increased morbidity and mortality, particularly in geriatric patient populations. The efficacy of clopidogrel reversal with platelet transfusions and DDAVP remains unclear. Warfarin use is best treated with the algorithm-driven use of plasma, vitamin K, prothrombin complex concentrates (PCCs) and possibly recombinant factor VIIa depending upon specific patient and injury factors. Optimal treatment for direct thrombin and factor Xa inhibitors has yet to be developed, but PCCs are promising for rivaroxaban and apixaban while dabigatran is best treated with medication cessation and the possible addition of activated PCCs or hemodialysis.

Conclusion

New developments in reversal of the ACAP medications are promising, particularly PCCs for warfarin and the factor Xa inhibitors. Function assays and clear antidotes are needed for the thrombin and Xa inhibitors. Research on outcomes and appropriate treatments is actively ongoing.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Top 20 global products 2012 http://www.imshealth.com/deployedfiles/ims/Global/Content/Corporate/Press%20Room/Top-Line%20Market%20Data%20&%20Trends/Top_20_Global_Products_2012_2.pdf: IMS institute for healthcare informatics (2012). Accessed 17 Dec 2013.

  2. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857–67.

    PubMed  Google Scholar 

  3. Top 25 medicines by dispensed prescriptions (US). http://www.imshealth.com/deployedfiles/imshealth/Global/Content/Corporate/Press%20Room/2012_U.S/Top_25_Medicines_Dispensed_Prescriptions_U.S.pdf2013 Accessed 17 Dec 2013.

  4. Bauer KA. Dabigatran, ROCKET atrial fibrillation, and beyond: basic science, mechanisms of agents, monitoring, and reversal. Stroke. 2013;44:S38–40.

    PubMed  Google Scholar 

  5. Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D’Angelo A, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet. 1996;348:423–8.

    CAS  PubMed  Google Scholar 

  6. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51.

    CAS  PubMed  Google Scholar 

  7. Xu YHA, Simpson CS, Dowlatshahi D, Johnson AP. Prescribing patterns of novel oral anticoagulants following regulatory approval for atrial fibrillation in Ontario, Canada: a population-based descriptive analysis. CMAJ Open. 2013;1:E115–9.

    PubMed Central  PubMed  Google Scholar 

  8. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–91.

    CAS  PubMed  Google Scholar 

  9. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–92.

    CAS  PubMed  Google Scholar 

  10. FDA Drug Safety Communication: Update on the risk for serious bleeding events with the anticoagulant Pradaxa (dabigatran). http://www.fda.gov/Drugs/DrugSafety/ucm326580.htm2012. Accessed 15 Dec 2013.

  11. Wood S. Dabigatran: 260 fatal bleeds since approval worldwide. http://www.medscape.com/viewarticle/753816: MEDSCAPE (2011). Accessed 15 Dec 2013.

  12. Ott MM, Eriksson E, Vanderkolk W, Christianson D, Davis A, Scholten D. Antiplatelet and anticoagulation therapies do not increase mortality in the absence of traumatic brain injury. J Trauma. 2010;68:560–3.

    CAS  PubMed  Google Scholar 

  13. Bonville DJ, Ata A, Jahraus CB, Arnold-Lloyd T, Salem L, Rosati C, et al. Impact of preinjury warfarin and antiplatelet agents on outcomes of trauma patients. Surgery. 2011;150:861–8.

    PubMed  Google Scholar 

  14. Moore MM, Pasquale MD, Badellino M. Impact of age and anticoagulation: need for neurosurgical intervention in trauma patients with mild traumatic brain injury. J Trauma Acute Care Surg. 2012;73:126–30.

    PubMed  Google Scholar 

  15. Garra G, Nashed AH, Capobianco L. Minor head trauma in anticoagulated patients. Acad Emerg Med. 1999;6:121–4.

    CAS  PubMed  Google Scholar 

  16. Gittleman AM, Ortiz AO, Keating DP, Katz DS. Indications for CT in patients receiving anticoagulation after head trauma. AJNR Am J Neuroradiol. 2005;26:603–6.

    PubMed  Google Scholar 

  17. Kaen A, Jimenez-Roldan L, Arrese I, Delgado MA, Lopez PG, Alday R, et al. The value of sequential computed tomography scanning in anticoagulated patients suffering from minor head injury. J Trauma. 2010;68:895–8.

    CAS  PubMed  Google Scholar 

  18. Levine M, Wyler B, Lovecchio F, Roque P, Raja AS. Risk of intracranial injury after minor head trauma in patients with pre-injury use of clopidogrel. Am J Emerg Med. 2014;32:71–4.

    PubMed  Google Scholar 

  19. Brewer ES, Reznikov B, Liberman RF, Baker RA, Rosenblatt MS, David CA, et al. Incidence and predictors of intracranial hemorrhage after minor head trauma in patients taking anticoagulant and antiplatelet medication. J Trauma. 2011;70:E1–5.

    CAS  PubMed  Google Scholar 

  20. Nishijima DK, Offerman SR, Ballard DW, Vinson DR, Chettipally UK, Rauchwerger AS, et al. Risk of traumatic intracranial hemorrhage in patients with head injury and preinjury warfarin or clopidogrel use. Acad Emerg Med. 2013;20:140–5.

    PubMed Central  PubMed  Google Scholar 

  21. Nishijima DK, Offerman SR, Ballard DW, Vinson DR, Chettipally UK, Rauchwerger AS, et al. Immediate and delayed traumatic intracranial hemorrhage in patients with head trauma and preinjury warfarin or clopidogrel use. Ann Emerg Med. 2012;59(460–8):e1–7.

    PubMed  Google Scholar 

  22. Peck KA, Sise CB, Shackford SR, Sise MJ, Calvo RY, Sack DI, et al. Delayed intracranial hemorrhage after blunt trauma: are patients on preinjury anticoagulants and prescription antiplatelet agents at risk? J Trauma. 2011;71:1600–4.

    CAS  PubMed  Google Scholar 

  23. Menditto VG, Lucci M, Polonara S, Pomponio G, Gabrielli A. Management of minor head injury in patients receiving oral anticoagulant therapy: a prospective study of a 24-hour observation protocol. Ann Emerg Med. 2012;59:451–5.

    PubMed  Google Scholar 

  24. Choudhry OJ, Prestigiacomo CJ, Gala N, Slasky S, Sifri ZC. Delayed neurological deterioration after mild head injury: cause, temporal course, and outcomes. Neurosurgery. 2013;73:753–60 (discussion 60).

    PubMed  Google Scholar 

  25. Cohen DB, Rinker C, Wilberger JE. Traumatic brain injury in anticoagulated patients. J Trauma. 2006;60:553–7.

    PubMed  Google Scholar 

  26. Patel NY, Hoyt DB, Nakaji P, Marshall L, Holbrook T, Coimbra R, et al. Traumatic brain injury: patterns of failure of nonoperative management. J Trauma. 2000;48:367–74 (discussion 74–75).

    CAS  PubMed  Google Scholar 

  27. Washington CW, Grubb RL Jr. Are routine repeat imaging and intensive care unit admission necessary in mild traumatic brain injury? J Neurosurg. 2012;116:549–57.

    PubMed  Google Scholar 

  28. Sifri ZC, Homnick AT, Vaynman A, Lavery R, Liao W, Mohr A, et al. A prospective evaluation of the value of repeat cranial computed tomography in patients with minimal head injury and an intracranial bleed. J Trauma. 2006;61:862–7.

    PubMed  Google Scholar 

  29. Fabbri A, Servadei F, Marchesini G, Bronzoni C, Montesi D, Arietta L. Antiplatelet therapy and the outcome of subjects with intracranial injury: the Italian SIMEU study. Crit Care. 2013;17:R53.

    PubMed Central  PubMed  Google Scholar 

  30. Flibotte JJ, Hagan N, O’Donnell J, Greenberg SM, Rosand J. Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage. Neurology. 2004;63:1059–64.

    CAS  PubMed  Google Scholar 

  31. Wang MC, Linnau KF, Tirschwell DL, Hollingworth W. Utility of repeat head computed tomography after blunt head trauma: a systematic review. J Trauma. 2006;61:226–33.

    PubMed  Google Scholar 

  32. Karni A, Holtzman R, Bass T, Zorman G, Carter L, Rodriguez L, et al. Traumatic head injury in the anticoagulated elderly patient: a lethal combination. Am Surg. 2001;67:1098–100.

    CAS  PubMed  Google Scholar 

  33. Mina AA, Bair HA, Howells GA, Bendick PJ. Complications of preinjury warfarin use in the trauma patient. J Trauma. 2003;54:842–7.

    PubMed  Google Scholar 

  34. Lavoie A, Ratte S, Clas D, Demers J, Moore L, Martin M, et al. Preinjury warfarin use among elderly patients with closed head injuries in a trauma center. J Trauma. 2004;56:802–7.

    PubMed  Google Scholar 

  35. Ohm C, Mina A, Howells G, Bair H, Bendick P. Effects of antiplatelet agents on outcomes for elderly patients with traumatic intracranial hemorrhage. J Trauma. 2005;58:518–22.

    CAS  PubMed  Google Scholar 

  36. Franko J, Kish KJ, O’Connell BG, Subramanian S, Yuschak JV. Advanced age and preinjury warfarin anticoagulation increase the risk of mortality after head trauma. J Trauma. 2006;61:107–10.

    CAS  PubMed  Google Scholar 

  37. Pieracci FM, Eachempati SR, Shou J, Hydo LJ, Barie PS. Degree of anticoagulation, but not warfarin use itself, predicts adverse outcomes after traumatic brain injury in elderly trauma patients. J Trauma. 2007;63:525–30.

    CAS  PubMed  Google Scholar 

  38. Mina AA, Knipfer JF, Park DY, Bair HA, Howells GA, Bendick PJ. Intracranial complications of preinjury anticoagulation in trauma patients with head injury. J Trauma. 2002;53:668–72.

    CAS  PubMed  Google Scholar 

  39. Jones K, Sharp C, Mangram AJ, Dunn EL. The effects of preinjury clopidogrel use on older trauma patients with head injuries. Am J Surg. 2006;192:743–5.

    CAS  PubMed  Google Scholar 

  40. Ivascu FA, Howells GA, Junn FS, Bair HA, Bendick PJ, Janczyk RJ. Rapid warfarin reversal in anticoagulated patients with traumatic intracranial hemorrhage reduces hemorrhage progression and mortality. J Trauma. 2005;59:1131–7 (discussion 7–9).

    CAS  PubMed  Google Scholar 

  41. Nishijima DK, Shahlaie K, Sarkar K, Rudisill N, Holmes JF. Risk of unfavorable long-term outcome in older adults with traumatic intracranial hemorrhage and anticoagulant or antiplatelet use. Am J Emerg Med. 2013;31:1244–7.

    PubMed Central  PubMed  Google Scholar 

  42. Wong DK, Lurie F, Wong LL. The effects of clopidogrel on elderly traumatic brain injured patients. J Trauma. 2008;65:1303–8.

    CAS  PubMed  Google Scholar 

  43. Livingston DH, Lavery RF, Mosenthal AC, Knudson MM, Lee S, Morabito D, et al. Recovery at one year following isolated traumatic brain injury: a Western Trauma Association prospective multicenter trial. J Trauma. 2005;59:1298–304 (discussion 304).

    PubMed  Google Scholar 

  44. Cotton BA, McCarthy JJ, Holcomb JB. Acutely injured patients on dabigatran. N Engl J Med. 2011;365:2039–40.

    PubMed  Google Scholar 

  45. Garber ST, Sivakumar W, Schmidt RH. Neurosurgical complications of direct thrombin inhibitors–catastrophic hemorrhage after mild traumatic brain injury in a patient receiving dabigatran. J Neurosurg. 2012;116:1093–6.

    PubMed  Google Scholar 

  46. Wassef SN, Abel TJ, Grossbach A, Viljoen SV, Jackson AW, Howard MA 3rd, et al. Traumatic intracranial hemorrhage in patients taking dabigatran: report of 3 cases and review of the literature. Neurosurgery. 2013;73:E368–73 (discussion E73–E74).

    PubMed  Google Scholar 

  47. Inui TS, Parina R, Chang DC, Coimbra R. Mortality after ground-level fall in the elderly patient taking oral anticoagulation for atrial fibrillation/flutter: a long-term analysis of risk versus benefit. J Trauma Acute Care Surg. 2014;76:642–50.

    CAS  PubMed  Google Scholar 

  48. Coimbra R, Hoyt DB, Anjaria DJ, Potenza BM, Fortlage D, Hollingsworth-Fridlund P. Reversal of anticoagulation in trauma: a North-American survey on clinical practices among trauma surgeons. J Trauma. 2005;59:375–82.

    PubMed  Google Scholar 

  49. Thigpen JL, Limdi NA. Reversal of oral anticoagulation. Pharmacotherapy. 2013;33(11):1199–213.

    CAS  PubMed Central  PubMed  Google Scholar 

  50. NovoSeven highlights of prescribing information. http://www.novo-pi.com/novosevenrt.pdf: NovoNordisk (2013).

  51. Profilnine SD-factor ix complex. http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM261964.pdf: Grifols Biologicals Inc. (2010).

  52. KCentra—quick reference guide. http://www.kcentra.com/docs/Kcentra_Quick_Reference_Guide.pdf: CSL Behring (2013).

  53. Package leaflet: information for the user. http://www.sanquin.nl/repository/documenten/en/prod-en-dienst/plasmaproducten/Cofact/Package_leaflet.pdf: Sanquin (2011).

  54. Octaplex product monograph. http://www.octapharma.ca/fileadmin/user_upload/octapharma.ca/20120613_PM_Octaplex_approved.pdf: OctaPharma (2012).

  55. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360:354–62.

    CAS  PubMed  Google Scholar 

  56. Bansal V, Fortlage D, Lee J, Doucet J, Potenza B, Coimbra R. A new clopidogrel (Plavix) point-of-care assay: rapid determination of antiplatelet activity in trauma patients. J Trauma. 2011;70:65–9 (discussion 9–70).

    CAS  PubMed  Google Scholar 

  57. Short S, Kram B, Taylor S, Cheng J, Ali K, Vasquez D. Effect of platelet inhibition on bleeding complications in trauma patients on preinjury clopidogrel. J Trauma Acute Care Surg. 2013;74:1419–24.

    CAS  PubMed  Google Scholar 

  58. Nishijima DK, Zehtabchi S, Berrong J, Legome E. Utility of platelet transfusion in adult patients with traumatic intracranial hemorrhage and preinjury antiplatelet use: a systematic review. J Trauma Acute Care Surg. 2012;72:1658–63.

    PubMed  Google Scholar 

  59. McMillian WD, Rogers FB. Management of prehospital antiplatelet and anticoagulant therapy in traumatic head injury: a review. J Trauma. 2009;66:942–50.

    PubMed  Google Scholar 

  60. Downey DM, Monson B, Butler KL, Fortuna GR Jr, Saxe JM, Dolan JP, et al. Does platelet administration affect mortality in elderly head-injured patients taking antiplatelet medications? Am Surg. 2009;75:1100–3.

    PubMed  Google Scholar 

  61. Taylor G, Osinski D, Thevenin A, Devys JM. Is platelet transfusion efficient to restore platelet reactivity in patients who are responders to aspirin and/or clopidogrel before emergency surgery? J Trauma Acute Care Surg. 2013;74:1367–9.

    CAS  PubMed  Google Scholar 

  62. Levine M, Swenson S, McCormick T, Henderson SO, Thomas SH, Markland FS. Reversal of thienopyridine-induced platelet dysfunction following desmopressin administration. J Med Toxicol. 2013;9:139–43.

    CAS  PubMed Central  PubMed  Google Scholar 

  63. Ranucci M, Nano G, Pazzaglia A, Bianchi P, Casana R, Tealdi DG. Platelet mapping and desmopressin reversal of platelet inhibition during emergency carotid endarterectomy. J Cardiothorac Vasc Anesth. 2007;21:851–4.

    PubMed  Google Scholar 

  64. Leithauser B, Zielske D, Seyfert UT, Jung F. Effects of desmopressin on platelet membrane glycoproteins and platelet aggregation in volunteers on clopidogrel. Clin Hemorheol Microcirc. 2008;39:293–302.

    CAS  PubMed  Google Scholar 

  65. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133:160S–98S.

    CAS  PubMed  Google Scholar 

  66. Lubetsky A, Yonath H, Olchovsky D, Loebstein R, Halkin H, Ezra D. Comparison of oral vs intravenous phytonadione (vitamin K1) in patients with excessive anticoagulation: a prospective randomized controlled study. Arch Intern Med. 2003;163:2469–73.

    CAS  PubMed  Google Scholar 

  67. Stein DM, Dutton RP, Hess JR, Scalea TM. Low-dose recombinant factor VIIa for trauma patients with coagulopathy. Injury. 2008;39:1054–61.

    PubMed  Google Scholar 

  68. Harrison TD, Laskosky J, Jazaeri O, Pasquale MD, Cipolle M. “Low-dose” recombinant activated factor VII results in less blood and blood product use in traumatic hemorrhage. J Trauma. 2005;59:150–4.

    CAS  PubMed  Google Scholar 

  69. Narayan RK, Maas AI, Marshall LF, Servadei F, Skolnick BE, Tillinger MN. Recombinant factor VIIA in traumatic intracerebral hemorrhage: results of a dose-escalation clinical trial. Neurosurgery. 2008;62:776–86 (discussion 86–88).

    PubMed  Google Scholar 

  70. Brody DL, Aiyagari V, Shackleford AM, Diringer MN. Use of recombinant factor VIIa in patients with warfarin-associated intracranial hemorrhage. Neurocrit Care. 2005;2:263–7.

    PubMed Central  PubMed  Google Scholar 

  71. Ilyas C, Beyer GM, Dutton RP, Scalea TM, Hess JR. Recombinant factor VIIa for warfarin-associated intracranial bleeding. J Clin Anesth. 2008;20:276–9.

    CAS  PubMed  Google Scholar 

  72. Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, et al. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2008;358:2127–37.

    CAS  PubMed  Google Scholar 

  73. Thomas GO, Dutton RP, Hemlock B, Stein DM, Hyder M, Shere-Wolfe R, et al. Thromboembolic complications associated with factor VIIa administration. J Trauma. 2007;62:564–9.

    PubMed  Google Scholar 

  74. Levi M, Peters M, Buller HR. Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review. Crit Care Med. 2005;33:883–90.

    CAS  PubMed  Google Scholar 

  75. Taketomi T, Szlam F, Levy JH, Tanaka KA. Warfarin reversal with prothrombin complex concentrate confers better antifibrinolytic activity compared with recombinant activated factor VII. Blood Coagul Fibrinolysis. 2008;19:106–8.

    PubMed  Google Scholar 

  76. Stein DM, Dutton RP, Kramer ME, Scalea TM. Reversal of coagulopathy in critically ill patients with traumatic brain injury: recombinant factor VIIa is more cost-effective than plasma. J Trauma. 2009;66:63–72 (discussion 3–5).

    PubMed  Google Scholar 

  77. Schulman S, Bijsterveld NR. Anticoagulants and their reversal. Transfus Med Rev. 2007;21:37–48.

    PubMed  Google Scholar 

  78. Switzer JA, Rocker J, Mohorn P, Waller JL, Hughes D, Bruno A, et al. Clinical experience with three-factor prothrombin complex concentrate to reverse warfarin anticoagulation in intracranial hemorrhage. Stroke. 2012;43:2500–2.

    CAS  PubMed  Google Scholar 

  79. Holland L, Warkentin TE, Refaai M, Crowther MA, Johnston MA, Sarode R. Suboptimal effect of a three-factor prothrombin complex concentrate (Profilnine-SD) in correcting supratherapeutic international normalized ratio due to warfarin overdose. Transfusion. 2009;49:1171–7.

    CAS  PubMed  Google Scholar 

  80. Sarode R, Matevosyan K, Bhagat R, Rutherford C, Madden C, Beshay JE. Rapid warfarin reversal: a 3-factor prothrombin complex concentrate and recombinant factor VIIa cocktail for intracerebral hemorrhage. J Neurosurg. 2012;116:491–7.

    CAS  PubMed  Google Scholar 

  81. Baggs JH, Patanwala AE, Williams EM, Erstad BL. Dosing of 3-factor prothrombin complex concentrate for international normalized ratio reversal. Ann Pharmacother. 2012;46:51–6.

    CAS  PubMed  Google Scholar 

  82. Vigue B, Ract C, Tremey B, Engrand N, Leblanc PE, Decaux A, et al. Ultra-rapid management of oral anticoagulant therapy-related surgical intracranial hemorrhage. Intensive Care Med. 2007;33:721–5.

    CAS  PubMed  Google Scholar 

  83. Evans G, Luddington R, Baglin T. Beriplex P/N reverses severe warfarin-induced over anticoagulation immediately and completely in patients presenting with major bleeding. Br J Haematol. 2001;115:998–1001.

    CAS  PubMed  Google Scholar 

  84. Wong Y. Use of prothrombin complex concentrate for vitamin K antagonist reversal before surgical treatment of intracranial hemorrhage. Clin Med Insights Case Rep. 2011;4:1–6.

    PubMed Central  PubMed  Google Scholar 

  85. Pabinger-Fasching I. Warfarin-reversal: results of a phase III study with pasteurised, nanofiltrated prothrombin complex concentrate. Thromb Res. 2008;122(Suppl 2):S19–22.

    CAS  PubMed  Google Scholar 

  86. Ostermann H, Haertel S, Knaub S, Kalina U, Jung K, Pabinger I. Pharmacokinetics of Beriplex P/N prothrombin complex concentrate in healthy volunteers. Thromb Haemost. 2007;98:790–7.

    CAS  PubMed  Google Scholar 

  87. Song MM, Warne CP, Crowther MA. Prothrombin complex concentrate (PCC, Octaplex) in patients requiring immediate reversal of vitamin K antagonist anticoagulation. Thromb Res. 2012;129:526–9.

    CAS  PubMed  Google Scholar 

  88. Gatt A, Riddell A, van Veen JJ, Kitchen S, Tuddenham EG, Makris M. Optimizing warfarin reversal—an ex vivo study. J Thromb Haemost. 2009;7:1123–7.

    CAS  PubMed  Google Scholar 

  89. Pabinger I, Brenner B, Kalina U, Knaub S, Nagy A, Ostermann H. Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. J Thromb Haemost. 2008;6:622–31.

    CAS  PubMed  Google Scholar 

  90. Bhardwaj M, Bunsell R. Beriplex P/N: an alternative to fresh frozen plasma in severe haemorrhage. Anaesthesia. 2007;62:832–4.

    CAS  PubMed  Google Scholar 

  91. Schick KS, Fertmann JM, Jauch KW, Hoffmann JN. Prothrombin complex concentrate in surgical patients: retrospective evaluation of vitamin K antagonist reversal and treatment of severe bleeding. Crit Care. 2009;13:R191.

    PubMed Central  PubMed  Google Scholar 

  92. Cabral KP, Fraser GL, Duprey J, Gibbons BA, Hayes T, Florman JE, et al. Prothrombin complex concentrates to reverse warfarin-induced coagulopathy in patients with intracranial bleeding. Clin Neurol Neurosurg. 2013;115:770–4.

    PubMed  Google Scholar 

  93. Scott LJ. Prothrombin complex concentrate (Beriplex P/N). Drugs. 2009;69:1977–84.

    CAS  PubMed  Google Scholar 

  94. Dickneite G. Prothrombin complex concentrate versus recombinant factor VIIa for reversal of coumarin anticoagulation. Thromb Res. 2007;119:643–51.

    CAS  PubMed  Google Scholar 

  95. Sorensen B, Spahn DR, Innerhofer P, Spannagl M, Rossaint R. Clinical review: prothrombin complex concentrates—evaluation of safety and thrombogenicity. Crit Care. 2011;15:201.

    PubMed Central  PubMed  Google Scholar 

  96. Makris M, Watson HG. The management of coumarin-induced over-anticoagulation Annotation. Br J Haematol. 2001;114:271–80.

    CAS  PubMed  Google Scholar 

  97. Wojcik C, Schymik ML, Cure EG. Activated prothrombin complex concentrate factor VIII inhibitor bypassing activity (FEIBA) for the reversal of warfarin-induced coagulopathy. Int J Emerg Med. 2009;2:217–25.

    PubMed Central  PubMed  Google Scholar 

  98. Stangier J, Clemens A. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost. 2009;15(Suppl 1):9S–16S.

    CAS  PubMed  Google Scholar 

  99. Stangier J, Rathgen K, Stahle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol. 2007;64:292–303.

    CAS  PubMed Central  PubMed  Google Scholar 

  100. Stangier J, Rathgen K, Stahle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet. 2010;49:259–68.

    CAS  PubMed  Google Scholar 

  101. van Ryn J SP, Kink-Eiband M, Gansser D, Clemens A. Adsorption of dabigatran etexilate in water or dabigatran in pooled human plasma by activated charcoal in vitro. In: American Society of Hematology Annual Meeting; 05 Dec 2009.

  102. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011;124:1573–9.

    CAS  PubMed  Google Scholar 

  103. Majeed A, Schulman S. Bleeding and antidotes in new oral anticoagulants. Best Pract Res Clin Haematol. 2013;26:191–202.

    CAS  PubMed  Google Scholar 

  104. Lillo-Le Louet A, Wolf M, Soufir L, Galbois A, Dumenil AS, Offenstadt G, et al. Life-threatening bleeding in four patients with an unusual excessive response to dabigatran: implications for emergency surgery and resuscitation. Thromb Haemost. 2012;108:583–5.

    CAS  PubMed  Google Scholar 

  105. Wychowski MK, Kouides PA. Dabigatran-induced gastrointestinal bleeding in an elderly patient with moderate renal impairment. Ann Pharmacother. 2012;46:e10.

    PubMed  Google Scholar 

  106. Zhou W, Schwarting S, Illanes S, Liesz A, Middelhoff M, Zorn M, et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke. 2011;42:3594–9.

    PubMed  Google Scholar 

  107. Marlu R, Hodaj E, Paris A, Albaladejo P, Cracowski JL, Pernod G. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost. 2012;108:217–24.

    CAS  PubMed  Google Scholar 

  108. Dager WE, Gosselin RC, Roberts AJ. Reversing dabigatran in life-threatening bleeding occurring during cardiac ablation with factor eight inhibitor bypassing activity. Crit Care Med. 2013;41:e42–6.

    PubMed  Google Scholar 

  109. Ehrlich HJ, Henzl MJ, Gomperts ED. Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events. Haemophilia. 2002;8:83–90.

    CAS  PubMed  Google Scholar 

  110. Truumees E, Gaudu T, Dieterichs C, Geck M, Stokes J. Epidural hematoma and intraoperative hemorrhage in a spine trauma patient on Pradaxa (dabigatran). Spine (Phila Pa 1976). 2012;37:E863–5.

    Google Scholar 

  111. Warkentin TE, Margetts P, Connolly SJ, Lamy A, Ricci C, Eikelboom JW. Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. Blood. 2012;119:2172–4.

    CAS  PubMed  Google Scholar 

  112. Wanek MR, Horn ET, Elapavaluru S, Baroody SC, Sokos G. Safe use of hemodialysis for dabigatran removal before cardiac surgery. Ann Pharmacother. 2012;46:e21.

    PubMed  Google Scholar 

  113. Mueck W, Schwers S, Stampfuss J. Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring. Thromb J. 2013;11:10.

    CAS  PubMed Central  PubMed  Google Scholar 

  114. Rivaroxaban for reducing the risk of cardiovascular events (cardiovascular death, myocardial infarction and stroke) after acute coronary syndrome (ACS). http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ucm304757.pdf: Janssen research and development, LLC. Accessed 15 Dec 2013.

  115. Mueck W, Eriksson BI, Bauer KA, Borris L, Dahl OE, Fisher WD, et al. Population pharmacokinetics and pharmacodynamics of rivaroxaban—an oral, direct factor Xa inhibitor–in patients undergoing major orthopaedic surgery. Clin Pharmacokinet. 2008;47:203–16.

    CAS  PubMed  Google Scholar 

  116. Korber MK, Langer E, Ziemer S, Perzborn E, Gericke C, von Heymann C. Measurement and reversal of prophylactic and therapeutic peak levels of rivaroxaban: an in vitro study. Clin Appl Thromb Hemost. 2013 [Epub ahead of print].

  117. Escolar G, Fernandez-Gallego V, Arellano-Rodrigo E, Roquer J, Reverter JC, Sanz VV, et al. Reversal of apixaban induced alterations in hemostasis by different coagulation factor concentrates: significance of studies in vitro with circulating human blood. PLoS One. 2013;8:e78696.

    CAS  PubMed Central  PubMed  Google Scholar 

  118. Wong PC, Crain EJ, Xin B, Wexler RR, Lam PY, Pinto DJ, et al. Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J Thromb Haemost. 2008;6:820–9.

    CAS  PubMed  Google Scholar 

  119. Samama MM, Contant G, Spiro TE, Perzborn E, Le Flem L, Guinet C, et al. Laboratory assessment of rivaroxaban: a review. Thromb J. 2013;11:11.

    CAS  PubMed Central  PubMed  Google Scholar 

  120. Perzborn E, Roehrig S, Straub A, Kubitza D, Mueck W, Laux V. Rivaroxaban: a new oral factor Xa inhibitor. Arterioscler Thromb Vasc Biol. 2010;30:376–81.

    CAS  PubMed  Google Scholar 

  121. Kubitza D, Becka M, Mueck W, Halabi A, Maatouk H, Klause N, et al. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct factor Xa inhibitor. Br J Clin Pharmacol. 2010;70:703–12.

    CAS  PubMed Central  PubMed  Google Scholar 

  122. Raghavan N, Frost CE, Yu Z, He K, Zhang H, Humphreys WG, et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos. 2009;37:74–81.

    CAS  PubMed  Google Scholar 

  123. Perzborn E, Gruber A, Tinel H, Marzec UM, Buetehorn U, Buchmueller A, et al. Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates. Thromb Haemost. 2013;110:162–72.

    CAS  PubMed  Google Scholar 

  124. Godier A, Miclot A, Le Bonniec B, Durand M, Fischer AM, Emmerich J, et al. Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model. Anesthesiology. 2012;116:94–102.

    CAS  PubMed  Google Scholar 

  125. Wong PC, White A, Luettgen J. Inhibitory effect of apixaban compared with rivaroxaban and dabigatran on thrombin generation assay. Hosp Pract. 1995;2013(41):19–25.

    Google Scholar 

  126. Zhou W, Zorn M, Nawroth P, Butehorn U, Perzborn E, Heitmeier S, et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with rivaroxaban. Stroke. 2013;44:771–8.

    CAS  PubMed  Google Scholar 

  127. Martin AC, Le Bonniec B, Fischer AM, Marchand-Leroux C, Gaussem P, Samama CM, et al. Evaluation of recombinant activated factor VII, prothrombin complex concentrate, and fibrinogen concentrate to reverse apixaban in a rabbit model of bleeding and thrombosis. Int J Cardiol. 2013;168:4228–33.

    PubMed  Google Scholar 

  128. Lu G, DeGuzman FR, Hollenbach SJ, Karbarz MJ, Abe K, Lee G, et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med. 2013;19:446–51.

    CAS  PubMed  Google Scholar 

  129. Millar CM, Lane DA. Blocking direct inhibitor bleeding. Blood. 2013;121:3543–4.

    CAS  PubMed  Google Scholar 

Download references

Conflict of interest

Allison E. Berndtson and Raul Coimbra declare that they have no conflict of interest.

Compliance with Ethics Guidelines

This article does not contain any studies with human or animal subjects performed by the any of the authors.

Author information

Authors and Affiliations

  1. Division of Trauma, Surgical Critical Care and Burns, Department of Surgery, University of California San Diego, 200 West Arbor Drive, Mail Code 8896, San Diego, CA, 92103, USA

    A. E. Berndtson & R. Coimbra

Authors
  1. A. E. Berndtson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Coimbra
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. Coimbra.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Berndtson, A.E., Coimbra, R. The epidemic of pre-injury oral antiplatelet and anticoagulant use. Eur J Trauma Emerg Surg 40, 657–669 (2014). https://doi.org/10.1007/s00068-014-0404-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00068-014-0404-9

Keywords

Search

Navigation